Antitrust Law Daily Wrap Up, ANTITRUST—E.D. Pa.: Humana’s generic-drug price-fixing claims will proceed to bellwether trial, (Aug 6, 2026)

By Martin A. Steinberg, J.D.

The court denied generic drugmakers’ bid for summary judgment, finding that a jury must decide whether fraudulent concealment tolled Humana’s antitrust claims.

The federal district court in Philadelphia denied generic drug manufacturers’ motion for partial summary judgment seeking dismissal of Humana Inc.’s Sherman Act claims concerning an alleged Theophylline conspiracy and an overarching conspiracy to fix prices and allocate markets for generic drugs. Although the court rejected Humana’s argument that state-filed antitrust actions triggered government-proceeding tolling under the Clayton Act and found that American Pipe tolling provided only limited relief, it held that Humana presented sufficient evidence of fraudulent concealment and reasonable diligence to create genuine disputes of material fact. The court concluded that a jury must decide whether the manufacturers concealed the alleged conspiracies and whether Humana should have discovered its claims before August 3, 2014 (In Re: Generic Pharmaceuticals Pricing Antitrust Litigation, No. 2:18-cv-03299-CMR (E.D. Pa. Aug. 4, 2026)).

Background. Humana Inc.’s lawsuit is part of multidistrict litigation in the Eastern District of Pennsylvania alleging that generic drug manufacturers conspired to fix prices and allocate markets. Filed in August 2018 and later amended to assert federal and state antitrust claims involving numerous generic drugs, the case has been selected as the MDL’s initial bellwether trial.

The summary-judgment motions concerned two Sherman Act claims: Count 91, alleging a conspiracy to manipulate the price and market for Theophylline beginning in 2014, and Count 106, alleging a broader conspiracy affecting multiple generic drugs. Defendants argued that claims based on conduct predating August 3, 2014, were barred by the four-year statute of limitations.

Humana contended that the limitations period was tolled by government antitrust proceedings, class actions brought by direct purchasers and end payors, and defendants’ fraudulent concealment. Defendants maintained that Humana was on inquiry notice by August 2013, when its employees began investigating price increases and discussing possible collusion. Humana responded that its investigation also identified legitimate explanations, including drug shortages, increased manufacturing costs, and supply constraints, and that defendants’ alleged secrecy and misleading explanations prevented it from discovering the conspiracies earlier.

In separate proceedings in the MDL, the court on July 16, 2026, approved settlements resolving direct purchasers’ generic-drug price-fixing claims. The settlements currently total approximately $62.26 million and could increase under most-favored-nation provisions.

The Humana bellwether trial is scheduled to begin on September 14, 2026, following jury selection.

Accrual. Federal antitrust claims generally accrue when a defendant commits an act that injures the plaintiff, triggering the Sherman Act’s four-year statute of limitations. A later overt act may create a new claim, but it does not revive claims for injuries caused by earlier acts outside the limitations period. The parties agreed that Humana could pursue injuries arising from purchases made after August 3, 2014, four years before it filed suit.

The dispute concerned whether Humana’s earlier claims were tolled. Defendants argued that Humana was on inquiry notice by August 15, 2013, when its employees began investigating rising generic-drug prices and considering possible collusion. Under the Third Circuit’s two-step inquiry-notice analysis, defendants must first identify “storm warnings” sufficient to alert a reasonable person to probable wrongdoing. The burden then shifts to Humana to show that it exercised reasonable diligence but still could not discover the alleged misconduct.

Humana alleged antitrust violations dating back as early as 2011. It argued that claims predating August 3, 2014, remained timely under government-proceeding tolling, class-action tolling under American Pipe v. Utah, 414 U.S. 538 (1974), and fraudulent concealment. By the time of the court’s decision, the disputed federal claims were limited to Count 91, concerning an alleged Theophylline conspiracy beginning in 2014, and Count 106, alleging an overarching conspiracy affecting the generic-drug market.

Timeliness of claims. Next, the court considered whether Humana may pursue Sherman Act claims arising before August 3, 2014, under three tolling theories: government-proceeding tolling, American Pipe class-action tolling, and fraudulent concealment.

The court first rejected Humana’s argument that lawsuits filed by several states in 2016 and 2017 suspended the limitations period under Section 16(i) of the Clayton Act. Although that provision is construed broadly, it applies only when the United States institutes a civil or criminal antitrust proceeding. Because those actions were brought by states rather than the United States, they did not toll Humana’s claims. The court noted, however, that federal criminal prosecutions of generic-drug executives might have supported tolling had the parties properly raised that issue.

The court next addressed American Pipe tolling, under which the filing of a class action suspends the statute of limitations for putative class members. Humana argued that direct-purchaser and end-payor class actions preserved its Theophylline and overarching-conspiracy claims. The court found that the end-payor plaintiffs’ June 7, 2018 complaint was the first class complaint asserting both claims. American Pipe therefore extended the limitations period only to June 7, 2014, providing Humana with limited additional time but not fully preserving all earlier claims.

The principal issue was fraudulent concealment. To obtain tolling on that basis, Humana had to present sufficient evidence that defendants affirmatively concealed the alleged conspiracies, that Humana exercised reasonable diligence, and that it neither knew nor reasonably should have known the facts supporting its claims until within the limitations period. Defendants argued that Humana was on inquiry notice by August 2013 because its employees were investigating rising generic-drug prices, discussing possible collusion, referring to “fair share” practices, and considering whether to contact the Federal Trade Commission.

Humana responded with evidence that defendants allegedly took deliberate steps to hide their conduct. According to the record, employees of several manufacturers exchanged pricing and market information orally, avoided email and text messages, used code words, instructed colleagues not to identify sources, and concealed communications with competitors. Humana also cited evidence that manufacturers gave customers misleading explanations for price increases, including claims of higher production costs, raw-material shortages, supply problems, regulatory expenses, and industry-wide changes, even when internal communications allegedly reflected agreements not to compete, efforts to preserve market shares, or coordinated price increases.

The court also found evidence that Humana investigated the price increases rather than ignoring them. Humana employees reviewed market conditions, consulted industry publications, analyzed supply shortages and manufacturing costs, considered competitive bids, attempted to negotiate lower prices, and developed strategies to reduce the financial impact. The information available at the time identified several plausible, non-collusive explanations for the increases. The court therefore rejected defendants’ position that Humana’s internal references to possible collusion or “fair share” pricing necessarily established inquiry notice as a matter of law.

The court concluded that Humana had produced enough evidence to create genuine disputes over whether defendants concealed the alleged Theophylline and overarching conspiracies, whether Humana acted with reasonable diligence, and when Humana should have discovered the basis for its claims. A jury must resolve those issues. Accordingly, the court denied defendants’ motion for partial summary judgment on Counts 91 and 106.

The Case is No. 2:18-cv-03299-CMR.

Judge: Rufe, C.

Attorneys: James Caleigh MacDonald (Schneider Wallace Cottrell Kim LLP) for Humana Inc. Sheron Korpus (Kasowitz LLP) for Actavis Elizabeth, LLC.

Companies: Humana Inc.; Actavis Elizabeth, LLC

MainStory: TopStory Antitrust PennsylvaniaNews GCNNews